Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States

Table 2 Inpatient outcomes of coronavirus disease 2019 hospitalizations with and without metabolic dysfunction-associated steatotic liver disease, n (%)

Secondary outcomes	No MASLD	MASLD	P value
Total hospitalizations	2210	2210
ARDS	125 (5.7)	160 (7.2)	0.032
Hypoxic respiratory failure	1105 (50.0)	1220 (55.2)	< 0.001
Bacterial pneumonia	35 (1.6)	45 (2.0)	0.26
Diarrhea	185 (8.4)	145 (6.6)	0.022
Septic shock	60 (2.7)	115 (5.2)	< 0.001
Supraventricular tachycardia	25 (1.1)	30 (1.4)	0.5
Ventricular tachycardia	10 (0.5)	30 (1.4)	0.001
Atrial fibrillation	165 (7.5)	170 (7.7)	0.78
Aflutter	100 (4.5)	80 (3.6)	0.13
Pulmonary embolism	35 (1.6)	30 (1.4)	0.53
Deep venous thrombosis	75 (3.4)	65 (2.9)	0.39
Compensated cirrhosis	635 (28.7)	635 (28.7)	1
Decompensated cirrhosis	45 (2.0)	45 (2.0)	1

ARDS: Acute respiratory distress syndrome; MASLD: Metabolic dysfunction-associated steatotic liver disease.